Analyzing genetic and biological markers in idiopathic pulmonary fibrosis

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to identify genetic and biological markers that may predict the decline in lung function in patients with idiopathic pulmonary fibrosis (IPF). Participants, who must be treated at the Simmons Center, will undergo various tests including blood draws, pulmonary function tests, echocardiograms, and CT scans, along with completing questionnaires about their symptoms. Follow-up visits will occur every 3-4 months to collect additional blood samples and assess changes in symptoms. If a patient experiences a rapid decline in lung function, a bronchoscopy will be performed to gather further data for analysis.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients who are 18 or older
* Diagnosis of Idiopathic Pulmonary Fibrosis
* Treated at the Simmons Center

Exclusion Criteria:

* Other Lung Illness

Where it's running

• Michelle F MacPherson
  Pittsburgh, Pennsylvania, United States Recruiting

Study contacts

• Principal investigator: Kevin F Gibson, MD — University of Pittsburgh - Dorothy P. and Richard P. Simmons Center for Interstitial Lung Disease
• Study coordinator: Michelle MacPherson, MAT
• Email: macphersonmj@upmc.edu
• Phone: 412-647-4537

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• New IPF drug ORJ-001 tested in adults with IPF

  A phase 2 study tests ORJ-001 versus placebo in adults with idiopathic pulmonary fibrosis to see if it is tolerated and whether it helps lung function.

  Recruiting at 2 sites Phase 2 Oorja Bio, Inc. · Doral, Florida and 1 other locations · NCT07869147

• Nalbuphine ER for IPF-related chronic cough

  This study tests whether extended-release nalbuphine tablets can reduce chronic cough in people with idiopathic pulmonary fibrosis.

  Recruiting at 4 sites Phase 3 Trevi Therapeutics · Wilmington, Delaware and 3 other locations · NCT07868419

• Inspiratory Flow Rate Capability in Pulmonary Fibrosis Patients

  This observational study tests how fast patients with IPF or PPF can inhale through dry powder inhalers with different resistances.

  Recruiting Shanghai Pulmonary Hospital, Shanghai, China · Shanghai, Shanghai Municipality · NCT07820254

• Photon-counting CT vs standard HRCT to help diagnose IPF and other ILDs

  This study tests whether photon-counting CT can improve identifying IPF and other ILDs compared with standard HRCT for patients discussed in multidisciplinary teams.

  Recruiting Istituto Clinico Humanitas · Rozzano, Italy · NCT07790614

• Rentosertib by mouth for people with idiopathic pulmonary fibrosis

  This is a randomized, placebo-controlled test to see if Rentosertib helps adults with idiopathic pulmonary fibrosis when taken as a pill.

  Recruiting at 12 sites Phase 3 InSilico Medicine Hong Kong Limited · Hefei, Anhui and 46 other locations · NCT07687459

• Inhaled nintedanib powder for IPF in adults

  This study tests whether an inhaled form of nintedanib can safely help adults with idiopathic pulmonary fibrosis.

  Recruiting Phase 2 Mannkind Corporation · Windsor, Ontario · NCT07679893

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.